|
|
Volumn 8, Issue 3, 2002, Pages 199-
|
|
Promising drug is victim of bad business
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY;
IRINOTECAN;
NEW DRUG;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
COLON CANCER;
COMMERCIAL PHENOMENA;
DRUG RESEARCH;
FINANCIAL MANAGEMENT;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LAW SUIT;
NOTE;
PATENT;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
RELIABILITY;
SIDE EFFECT;
STANDARD;
UNITED STATES;
|
|
EID: 0036129433
PISSN: 10788956
EISSN: None
Source Type: Journal
DOI: 10.1038/nm0302-199a Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|